Summary not available.
Summary not available.
Summary not available.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has provided an update on its drug discovery business unit's partnering discussions. The company utilizes a proprietary transcriptome-informed approach to enhance drug discovery, combining RNA profiling technologies with machine learning in drug candidate optimization. Positive preliminary interest from pharmaceutical companies has been noted, driven by HTG’s unique methodology, which aims for higher efficiency, lower risk profiles, and cost savings in drug development.
HTG is currently advancing two generations of drug candidates showing in vitro efficacy, expecting to enter preclinical development within months. The company is enthusiastic about future partnerships in oncology and neurodegenerative diseases, hoping to attract pharmaceutical collaborations for its drug discovery platform.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has achieved significant milestones in drug discovery during the first quarter of 2023. Key accomplishments include the in vitro demonstration of lead compounds' efficacy both as standalone therapies and in combination with standard care, showcasing the capabilities of HTG’s machine-learning medicinal chemistry platform. Additionally, the HTG EdgeSeq RNA profiling platform enabled the development of second-generation molecules, exhibiting improved efficacy. Furthermore, the AI-driven drug discovery engine successfully designed novel compounds based on transcriptomic data, potentially allowing for drug repurposing. The progress supports HTG’s oncology initiatives in liquid and solid tumors and underscores the scalability and flexibility of its drug discovery platform.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) announced that its proprietary HTG EdgeSeq technology will be featured in at least four scientific posters at the American Association for Cancer Research Annual Meeting from April 16-19, 2023, in Orlando, Florida. Esteemed institutions such as MD Anderson Cancer Center and Merck KGaA will present research utilizing HTG's platform for gene expression profiling. Highlights include the HTG Transcriptome Panel, which allows for comprehensive human transcriptome analysis with reduced sample requirements. The company emphasizes its collaboration with world-renowned research centers, showcasing the broad utility of its technology in precision medicine and drug discovery.
HTG Molecular Diagnostics (Nasdaq: HTGM) has announced significant advancements in its drug discovery business, particularly through its transcriptome-informed approach. A patent application was filed on December 28, 2022, targeting initial therapeutic compounds focusing on oncology and neurodegenerative diseases. The company’s oncology programs aim for preclinical development by late 2023, with multiple early discovery-stage programs planned. Management will host meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023, to discuss potential partnerships and developments.
HTG Molecular Diagnostics has reported preliminary unaudited revenue for 2022 of $6.4 million, which includes $2.7 million from its HTG Transcriptome Panel, making up 42% of total revenue. As of December 31, 2022, the company has $12.2 million in cash and cash equivalents. Despite not achieving the expected recovery in revenue, HTG saw a near 95% growth in revenue from Q3 to Q4 2022 and an increase of $1.3 million year-over-year for HTP revenue. The company aims to enhance efficiency in operations without compromising revenue generation.
HTG Molecular Diagnostics (Nasdaq: HTGM) has summarized its recent KOL webinar, "The Role of RNA Profiling in Drug Discovery and Analysis," held on December 13, 2022. Dr. Robert Spitale highlighted the significance of RNA profiling in drug development, noting HTG's EdgeSeq technology's capability to scale RNA profiling for enhanced compound screening. A practical example showcased the use of RNA profiling in differentiating mTOR-targeting compounds. HTG aims to leverage this scalable model across therapeutic areas to expedite the drug discovery process.
HTG Molecular Diagnostics has completed a public offering of 1,290,322 shares of its common stock and warrants, raising approximately $10 million. Each share was priced at $7.75, and the Series A-1 and A-2 warrants have an exercise price of $7.50 with varying expiration periods. The funds will be allocated for general corporate purposes, including R&D, clinical trials, and working capital. H.C. Wainwright & Co. served as the exclusive placement agent. This offering is registered with the SEC and follows relevant regulations.